Cover Image
Market Research Report
Product code 
1045526

Depression Drugs Market, by Drug Type (Antidepressants, Antipsychotics and Others), by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published: | Coherent Market Insights | 231 Pages | Delivery time: 2-3 business days

Price

Back to Top
Depression Drugs Market, by Drug Type (Antidepressants, Antipsychotics and Others), by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Published: December 15, 2021
Coherent Market Insights
Content info: 231 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Depression has emerged as a 'silent killer' in several regions across the world, particularly in urban cities. The prevalence of depression continues to grow rapidly with considerably high mortality and morbidity rate due to which, the healthcare sector continues its pursuit of novel medications and therapies. Antidepressants are prescribed in serious to mild mental health conditions such as major depression and anxiety. Antidepressant drug category is highly lucrative due to low availability of alternative drug therapies for the treatment of such disorders. Drug manufacturers are increasingly advancing the antidepressant drug category by introducing innovative therapies such as selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). Depression is one of the most common mental disorders, which are primarily treated by antidepressants. According to National Health Service Digital (NHS Digital), UK, antidepressant medication prescription observed the largest increase in 2016.

Market Dynamics

The global depression drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs are losing patent protection due to which increasing number of generic manufacturers are developing product variations, which in turn is boosting the growth of the market. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as depression are fueling growth of the market.

For instance, Fetzima, manufactured by Allergan Plc., is protected by three patents, which are expected to expire in 2031, 2032, and 2023.

However, life threatening side effects associated with these medications as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the depression drugs market.

Key features of the study:

  • This report provides an in-depth analysis of the global depression drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global depression drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson & Johnson, Sanofi S.A., Pfizer, Inc., Allergan plc, H. Lundbeck A/S, and Alkermes
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global depression drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global depression drugs market

Detailed Segmentation:

  • Global Depression Drugs Market, By Drug Type:
    • Antidepressants
      • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
      • Serotonin Modulators
      • Tricyclic & Tetracyclic Antidepressants
      • Atypical Antidepressants
    • Antipsychotics
    • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
  • Global Depression Drugs Market, By Indication:
    • Major Depressive Disorder (MDD)
    • Bipolar Disorder
    • Dysthymic Disorder
    • Postpartum Depression
    • Seasonal Affective Disorder (SAD)
    • Premenstrual Dysphoric Disorder (PMDD)
    • Others
  • Global Depression Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Depression Drugs Market, By Region:
    • North America
      • By Drug Type
      • Antidepressants
      • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
      • Serotonin Modulators
      • Tricyclic & Tetracyclic Antidepressants
      • Atypical Antidepressants
      • Antipsychotics
      • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
      • By Indication
      • Major Depressive Disorder (MDD)
      • Bipolar Disorder
      • Dysthymic Disorder
      • Postpartum Depression
      • Seasonal Affective Disorder (SAD)
      • Premenstrual Dysphoric Disorder (PMDD)
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • U.S.
      • Canada
    • Latin America
      • By Drug Type
      • Antidepressants
      • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
      • Serotonin Modulators
      • Tricyclic & Tetracyclic Antidepressants
      • Atypical Antidepressants
      • Antipsychotics
      • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
      • By Indication
      • Major Depressive Disorder (MDD)
      • Bipolar Disorder
      • Dysthymic Disorder
      • Postpartum Depression
      • Seasonal Affective Disorder (SAD)
      • Premenstrual Dysphoric Disorder (PMDD)
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type
      • Antidepressants
      • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
      • Serotonin Modulators
      • Tricyclic & Tetracyclic Antidepressants
      • Atypical Antidepressants
      • Antipsychotics
      • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
      • By Indication
      • Major Depressive Disorder (MDD)
      • Bipolar Disorder
      • Dysthymic Disorder
      • Postpartum Depression
      • Seasonal Affective Disorder (SAD)
      • Premenstrual Dysphoric Disorder (PMDD)
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type
      • Antidepressants
      • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
      • Serotonin Modulators
      • Tricyclic & Tetracyclic Antidepressants
      • Atypical Antidepressants
      • Antipsychotics
      • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
      • By Indication
      • Major Depressive Disorder (MDD)
      • Bipolar Disorder
      • Dysthymic Disorder
      • Postpartum Depression
      • Seasonal Affective Disorder (SAD)
      • Premenstrual Dysphoric Disorder (PMDD)
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type
      • Antidepressants
      • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
      • Serotonin Modulators
      • Tricyclic & Tetracyclic Antidepressants
      • Atypical Antidepressants
      • Antipsychotics
      • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
      • By Indication
      • Major Depressive Disorder (MDD)
      • Bipolar Disorder
      • Dysthymic Disorder
      • Postpartum Depression
      • Seasonal Affective Disorder (SAD)
      • Premenstrual Dysphoric Disorder (PMDD)
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type
      • Antidepressants
      • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
      • Serotonin Modulators
      • Tricyclic & Tetracyclic Antidepressants
      • Atypical Antidepressants
      • Antipsychotics
      • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
      • By Indication
      • Major Depressive Disorder (MDD)
      • Bipolar Disorder
      • Dysthymic Disorder
      • Postpartum Depression
      • Seasonal Affective Disorder (SAD)
      • Premenstrual Dysphoric Disorder (PMDD)
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Merck & Co., Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline plc
    • AstraZeneca Plc
    • Takeda Pharmaceutical Company Limited
    • Eli Lilly and Company
    • Johnson & Johnson
    • Sanofi S.A.
    • Pfizer, Inc.
    • Allergan plc
    • H. Lundbeck A/S
    • Alkermes

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI1307

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launch/Approval
  • Product Recalls
  • PEST Analysis
  • Treatment Received Among Adults With Major Depressive Episode
  • Regulatory Scenario
  • Algorithm for Management of Treatment Resistant Depression
  • Pipeline Analysis
  • Depression Therapeutics Dosage Range
  • Porter's Five Forces Analysis
  • Epidemiology
  • List Of U.S. FDA Approved Drugs for Depression
  • Reimbursement Scenario

4. Global Depression Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • Impact on Clinical Trials and Drug Development
  • Government Initiatives

5. Global Depression Drugs Market, By Drug Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
    • Serotonin Modulators
    • Tricyclic & Tetracyclic Antidepressants
    • Atypical Antidepressants
  • Antipsychotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Depression Drugs Market, By Indication, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Major Depressive Disorder (MDD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Bipolar Disorder
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Dysthymic Disorder
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Postpartum Depression
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Seasonal Affective Disorder (SAD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Premenstrual Dysphoric Disorder (PMDD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Depression Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Depression Drugs Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2028
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Region/Country, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Merck & Co., Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Allergan plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • H. Lundbeck A/S
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Alkermes
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact